Projects per year
Abstract
Anti–glomerular basement membrane (anti-GBM) disease is accompanied by insufficient antigen-specific regulatory T cells (Tregs) and clonally expanded antigen-specific conventional T cells. In particular, this applied to the immunodominant T cell autoepitope of type IV collagen, α3(IV)NC1135–145, presented by human leukocyte antigen–DRB1∗1501. Here, we investigated whether Tregs engineered to express GBM–T cell receptors (TCR) specific for α3(IV)NC1135–145 better suppress autoimmunity. The GBM-TCR Treg cell product exhibited a phenotypically stable Treg phenotype, produced α3(IV)NC1135–145–specific functional responses, and were superior suppressors of autoreactive conventional T cells and bystander conventional T cells compared to polyclonal Tregs or irrelevant TCR-transduced Tregs. We also found that GBM-TCR Tregs modulate other immune cells like dendritic cells and B cells to a more tolerogenic phenotype. Importantly, our findings support the development of GBM-TCR Tregs as a promising cell-based therapy for anti-GBM disease.
Original language | English |
---|---|
Pages (from-to) | 751-756 |
Number of pages | 6 |
Journal | Kidney International |
Volume | 107 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2025 |
Keywords
- anti–glomerular basement membrane (GBM) disease
- autoimmune disease
- cell therapy
- glomerulonephritis (GN)
- regulatory T cell (Treg)
- T-cell receptor (TCR)
Projects
- 2 Finished
-
A targeted regulatory cell based therapy to treat lupus
Ooi, J. (Primary Chief Investigator (PCI))
1/01/20 → 31/12/22
Project: Research
-
Treatments for glomerulonephritis that harness antigen specific regulatory cells
Ooi, J. (Primary Chief Investigator (PCI)) & Kitching, R. (Chief Investigator (CI))
1/01/18 → 31/12/20
Project: Research